Every material Form 8-K FRACTYL HEALTH, INC. has filed with the SEC since September 11, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Fractyl Health's board increased its size from nine to ten and appointed Michael Wartell as an independent Class III director effective November 2, 2026. Wartell will receive $40,000 per month in cash compensation under a director agreement, with a minimum of three months guaranteed unless he resigns.
Michael Wartell appointed effective November 2, 2026; term expires at the 2027 annual meeting
Cash compensation of $40,000 per month, payable monthly in advance, with a three-month minimum unless he resigns
Additional $3,000 for each day Board commitments exceed four hours outside normal Board duties
Wartell has not been appointed to any Board committee and will not join the Non-Employee Director Compensation Policy
Fractyl Health is reducing its workforce by about 45% to concentrate resources on its Revita program, and it will stop internal development of its Rejuva gene therapy program while it seeks strategic alternatives for that program. The company expects about $2 million in severance and related charges, mostly in the fourth quarter of 2026, and says its cash should last into the second quarter of 2027, with quarterly cash burn expected to fall about 50% to roughly $8 million by the end of that quarter.
Workforce reduction of approximately 45% of current headcount, expected to be substantially completed by November 2026
Severance and employee termination charges estimated at about $2 million, mostly in Q4 2026; other charges possible but not yet estimated
Jay Caplan retires as President and Chief Product Officer effective October 30, 2026; CEO Harith Rajagopalan appointed President
Cash runway extended into Q2 2027; quarterly operating cash burn expected to fall about 50% to roughly $8 million by end of Q2 2027
Fractyl Health reported topline six-month results from the Pivotal Cohort of its REMAIN-1 study of the Revita DMR System, a randomized, double-blind, sham-controlled trial. The company said Revita met its six-month co-primary endpoint, with participants retaining about 80% of GLP-1-induced weight loss versus 67% for sham, and the company plans a De Novo marketing application to the FDA in late Q4 2026.
Six-month co-primary endpoint met in the mITT population (N=308) with p=0.0023; weight regain of 5.1% for Revita versus 8.2% for sham
Post hoc analysis: participants receiving 20 cm or more of ablation had a mean weight regain of 3.8% (n=47); the second co-primary endpoint at 12 months is expected in Q1 2027
No device- or procedure-related serious adverse events, no deaths, and no unanticipated adverse device effects as of the September 24, 2026 data cut-off
Potential U.S. De Novo submission planned for late Q4 2026; potential U.S. launch in early 2028 if authorized
Fractyl Health said Nasdaq notified it on September 10, 2026 that its stock is subject to delisting because it did not regain compliance with the $1.00 minimum bid price requirement by September 9, 2026. The company intends to request a hearing before a Nasdaq Hearings Panel, which would keep its stock listed while the process runs, and has proposed a reverse stock split of 1-for-5 to 1-for-15 for stockholder approval.
Nasdaq letter dated September 10, 2026 says the stock is subject to delisting unless the company timely requests a hearing
Company did not meet the $1.00 minimum bid price within the 180-calendar day grace period ending September 9, 2026
Company intends to request a Panel hearing, which automatically stays suspension or delisting
Proxy statement filed August 24, 2026 seeks approval for a reverse split ranging from 1-for-5 to 1-for-15
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every FRACTYL HEALTH, INC. filing is on SEC EDGAR ↗. 8-K briefs of other companies →